JP2022536094A5 - - Google Patents
Info
- Publication number
- JP2022536094A5 JP2022536094A5 JP2021572049A JP2021572049A JP2022536094A5 JP 2022536094 A5 JP2022536094 A5 JP 2022536094A5 JP 2021572049 A JP2021572049 A JP 2021572049A JP 2021572049 A JP2021572049 A JP 2021572049A JP 2022536094 A5 JP2022536094 A5 JP 2022536094A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025116389A JP2025146855A (ja) | 2019-06-05 | 2025-07-10 | Ｔ細胞枯渇治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857744P | 2019-06-05 | 2019-06-05 | |
| US62/857,744 | 2019-06-05 | ||
| PCT/US2020/036494 WO2020247872A1 (en) | 2019-06-05 | 2020-06-05 | T-cell depleting therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116389A Division JP2025146855A (ja) | 2019-06-05 | 2025-07-10 | Ｔ細胞枯渇治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536094A JP2022536094A (ja) | 2022-08-12 |
| JPWO2020247872A5 JPWO2020247872A5 (https=) | 2023-06-02 |
| JP2022536094A5 true JP2022536094A5 (https=) | 2023-06-02 |
| JP7791716B2 JP7791716B2 (ja) | 2025-12-24 |
Family
ID=73652313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572049A Active JP7791716B2 (ja) | 2019-06-05 | 2020-06-05 | Ｔ細胞枯渇治療 |
| JP2025116389A Pending JP2025146855A (ja) | 2019-06-05 | 2025-07-10 | Ｔ細胞枯渇治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116389A Pending JP2025146855A (ja) | 2019-06-05 | 2025-07-10 | Ｔ細胞枯渇治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220249683A1 (https=) |
| EP (1) | EP3980034A4 (https=) |
| JP (2) | JP7791716B2 (https=) |
| CN (1) | CN114206358A (https=) |
| AU (1) | AU2020286508A1 (https=) |
| CA (1) | CA3140447A1 (https=) |
| WO (1) | WO2020247872A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3107378A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
| CA3107383A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03503887A (ja) * | 1988-02-03 | 1991-08-29 | エクソウマ コーポレーション | 自己免疫疾患に対する抗ｔ細胞イムノトキシンの治療的使用 |
| US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US20030229207A1 (en) * | 1991-12-13 | 2003-12-11 | Xoma Technology Ltd. | Modified antibody variable domains |
| US20060051355A1 (en) * | 1998-03-23 | 2006-03-09 | Van Oosterhout Ypke V | Methods and means for the treatment of immune-related diseases |
| US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| EP2430051B1 (en) * | 2009-05-14 | 2016-03-23 | Institut National de la Santé et de la Recherche Medicale | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases |
| US20150218220A1 (en) * | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
| JP6863900B2 (ja) * | 2015-03-09 | 2021-04-21 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規アマトキシン−抗体コンジュゲート |
| MX395639B (es) * | 2017-01-20 | 2025-03-25 | Heidelberg Pharma Res Gmbh | Composiciones y métodos para el agotamiento de células cd137+. |
| CA3079897A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
| WO2019108863A1 (en) * | 2017-11-29 | 2019-06-06 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
| CA3107383A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| SG11202110287QA (en) * | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
-
2020
- 2020-06-05 JP JP2021572049A patent/JP7791716B2/ja active Active
- 2020-06-05 WO PCT/US2020/036494 patent/WO2020247872A1/en not_active Ceased
- 2020-06-05 CA CA3140447A patent/CA3140447A1/en active Pending
- 2020-06-05 CN CN202080055730.5A patent/CN114206358A/zh active Pending
- 2020-06-05 AU AU2020286508A patent/AU2020286508A1/en active Pending
- 2020-06-05 EP EP20818567.8A patent/EP3980034A4/en not_active Withdrawn
-
2021
- 2021-12-03 US US17/457,607 patent/US20220249683A1/en active Pending
-
2025
- 2025-07-10 JP JP2025116389A patent/JP2025146855A/ja active Pending